Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | LDHA | P00338 | 11/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21261293 | 0.81 | KMT2A (0.38) | LMNAGAAKMT2AALDH1A1GSTP1 | |
| SCHEMBL21261263 | 0.80 | KMT2A (0.40) | LMNAGAAKMT2AALDH1A1GSTP1 | |
| SCHEMBL1129788 | 0.79 | LMNA (0.63) | LMNAGAAKMT2AALDH1A1KDM4E | |
| SCHEMBL21261302 | 0.76 | LMNA (0.59) | LMNAGAAKMT2AALDH1A1KDM4E | |
| SCHEMBL92986 | 0.76 | LMNA (0.59) | LMNAGAAKMT2AALDH1A1KDM4E | |
| SCHEMBL21261338 | 0.75 | LMNA (0.51) | LMNAGAAKMT2AALDH1A1KDM4E | |
| SCHEMBL21261296 | 0.74 | LMNA (0.47) | LMNAGAAKMT2AALDH1A1KDM4E | |
| SCHEMBL2466435 | 0.74 | LMNA (0.56) | LMNAGAAKMT2AALDH1A1KDM4E | |
| SCHEMBL9263666 | 0.73 | LMNA (0.56) | LMNAGAAKMT2AALDH1A1KDM4E | |
| SCHEMBL9264609 | 0.73 | LMNA (0.56) | LMNAGAAKMT2AALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11376228-B2 | Polysubstituted benzene, preparation method thereof, and method of using the same | GENIFARM LABORATORIES INC (CN) | 2022-07-05 | — | — | US | disclosed |
| CN-110143858-B | Polysubstituted benzene compound with bioactivity and preparation method and application thereof | 华南理工大学 | 2022-04-29 | — | — | CN | disclosed |
| EP-3753931-A1 | MULTI-SUBSTITUTED BENZENE COMPOUND HAVING BIOLOGICAL ACTIVITY, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Genifarm Laboratories Inc (CN) | 2020-12-23 | — | — | EP | disclosed |
| US-20200361893-A1 | POLYSUBSTITUTED BENZENE, PREPARATION METHOD THEREOF, AND METHOD OF USING THE SAME | SOUTH CHINA UNIVERSITY OF TECHNOLOGY (CN) | 2020-11-19 | — | — | US | disclosed |
| WO-2019153954-A1 | MULTI-SUBSTITUTED BENZENE COMPOUND HAVING BIOLOGICAL ACTIVITY, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 广州自远生物科技有限公司 | 2019-08-15 | — | — | WO | disclosed |
| WO-2019153954-A1 | MULTI-SUBSTITUTED BENZENE COMPOUND HAVING BIOLOGICAL ACTIVITY, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 广州自远生物科技有限公司 | 2019-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11376228-B2 | Polysubstituted benzene, preparation method thereof, and method of using the same | CBR1, CBR3, C1S | LMNA 1509/4885GAA 4258/4885KMT2A 2516/4885 |
| US-20200361893-A1 | POLYSUBSTITUTED BENZENE, PREPARATION METHOD THEREOF, AND METHOD OF USING THE SAME | CBR1, CBR3, C1S | LMNA 1509/4885GAA 4258/4885KMT2A 2516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.